Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Emily J. Goddard's publication output changed over time?
ScholarIQpublication output · 2022–2025
Output grew400% over the shown period — from 1 works in 2022 to 5 in 2025.
1
1
5
202220242025
What are the most-cited papers on Emily J. Goddard?
ScholarIQmost cited works
Three-dimensional Cd( <scp>ii</scp> ) porphyrin metal–organic frameworks for the colorimetric sensing of Electron donors
Hui Min Tay, Emily J. Goddard, Carol Hua
S95865439. 20226 Citations
Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Emily J. Goddard, James Haughton, James Lucas, Sophie Barlow, Timothy Fitzgerald, Alexander Litvintchouk, David Wu
Dermatology and Therapy. 20253 CitationsOPEN ACCESS
Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression
Francesco Pesce, Ancilla W. Fernandes, D. Clamp, Beatriz Asin, Emily J. Goddard, Liane Gillespie–Akar, Alice Eberhardt
Current Medical Research and Opinion. 20241 CitationsOPEN ACCESS
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
Ran Jin, James Haughton, Emily J. Goddard, Delphine Courmier, Waldemar Radziszewski, Rachael Meadows, James Piercy, Stanley Cohen
Rheumatology and Therapy. 20251 CitationsOPEN ACCESS
CO192 Exploring the Value of Total/Near Total Skin Clearance in Patients With a History of Moderate-Severe Psoriasis: A Real-World Survey
Aaron Keal, Bruno Kranz, Emily J. Goddard, James Hetherington, Oluwakayode Adejoro
Value in Health. 20250 Citations
Related on ScholarIQ
Adelphi Group (United Kingdom)
Institution
Three-dimensional Cd( <scp>ii</scp> ) porphyrin metal–organic frameworks for the colorimetric sensing of Electron donors
Paper
Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Paper
Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression
Paper
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
Paper
CO192 Exploring the Value of Total/Near Total Skin Clearance in Patients With a History of Moderate-Severe Psoriasis: A Real-World Survey
Paper